DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs
Identifieur interne : 000394 ( Istex/Corpus ); précédent : 000393; suivant : 000395DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs
Auteurs : Jie Ren ; Hefei Jiang ; Juan Zhao ; Wenqun Xin ; Yuanyuan Xu ; Xin Chen ; Kun HuSource :
- Cell Biology International [ 1065-6995 ] ; 2014-03.
Abstract
Cytotoxic activity of 5,7‐dimethoxy‐2‐phenyl‐N‐propylquinolin‐4‐amine (DMPPQA) was investigated in human colon cancer cells HCT‐116 and umbilical vein endothelial cell line HUVEC. The IC50 of DMPPQA on HCT‐116 and HUVEC cells were respectively 1.26 and 7.43 µM after 72 h treatment. DMPPQA inhibited the growth of HCT‐116 and HUVEC cells in concentration‐ and time‐dependent manners. Typical morphological changes of apoptotic body formation were seen after DMPPQA with Hoechst 33258 staining. FCM analysis showed that DMPPQA induced apoptosis, mitochondrial membrane potential loss (ΔΨm) and increase in the production of intracellular reactive oxygen species (ROS) of HCT‐116 cells. After treating with DMPPQA, apoptosis‐related protein expression of Bax, cytochrome c, caspase‐9, caspase‐3, PARP‐1 and P53 increased and Bcl‐2 protein expression decreased. DMPPQA treatment of HUVECs reduced cell migration and microcapillary tube formation in a Matrigel matrix. It also decreased VEGF protein expression. Thus DMPPQA acts as an angiogenesis inhibitor and induces cell apoptosis by a caspase‐dependent mitochondrial pathway.
Url:
DOI: 10.1002/cbin.10209
Links to Exploration step
ISTEX:8E8899FCB0D7AFCF310D3D1AC8CD4C12302F5117Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs</title><author><name sortKey="Ren, Jie" sort="Ren, Jie" uniqKey="Ren J" first="Jie" last="Ren">Jie Ren</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: renjie2006@163.com</mods:affiliation></affiliation></author><author><name sortKey="Jiang, Hefei" sort="Jiang, Hefei" uniqKey="Jiang H" first="Hefei" last="Jiang">Hefei Jiang</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation></author><author><name sortKey="Zhao, Juan" sort="Zhao, Juan" uniqKey="Zhao J" first="Juan" last="Zhao">Juan Zhao</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation></author><author><name sortKey="Xin, Wenqun" sort="Xin, Wenqun" uniqKey="Xin W" first="Wenqun" last="Xin">Wenqun Xin</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation></author><author><name sortKey="Xu, Yuanyuan" sort="Xu, Yuanyuan" uniqKey="Xu Y" first="Yuanyuan" last="Xu">Yuanyuan Xu</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation></author><author><name sortKey="Chen, Xin" sort="Chen, Xin" uniqKey="Chen X" first="Xin" last="Chen">Xin Chen</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation></author><author><name sortKey="Hu, Kun" sort="Hu, Kun" uniqKey="Hu K" first="Kun" last="Hu">Kun Hu</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: renjie2006@163.com</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8E8899FCB0D7AFCF310D3D1AC8CD4C12302F5117</idno><date when="2014" year="2014">2014</date><idno type="doi">10.1002/cbin.10209</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-TSV254Z3-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000394</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000394</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs</title><author><name sortKey="Ren, Jie" sort="Ren, Jie" uniqKey="Ren J" first="Jie" last="Ren">Jie Ren</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: renjie2006@163.com</mods:affiliation></affiliation></author><author><name sortKey="Jiang, Hefei" sort="Jiang, Hefei" uniqKey="Jiang H" first="Hefei" last="Jiang">Hefei Jiang</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation></author><author><name sortKey="Zhao, Juan" sort="Zhao, Juan" uniqKey="Zhao J" first="Juan" last="Zhao">Juan Zhao</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation></author><author><name sortKey="Xin, Wenqun" sort="Xin, Wenqun" uniqKey="Xin W" first="Wenqun" last="Xin">Wenqun Xin</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation></author><author><name sortKey="Xu, Yuanyuan" sort="Xu, Yuanyuan" uniqKey="Xu Y" first="Yuanyuan" last="Xu">Yuanyuan Xu</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation></author><author><name sortKey="Chen, Xin" sort="Chen, Xin" uniqKey="Chen X" first="Xin" last="Chen">Xin Chen</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation></author><author><name sortKey="Hu, Kun" sort="Hu, Kun" uniqKey="Hu K" first="Kun" last="Hu">Kun Hu</name><affiliation><mods:affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: renjie2006@163.com</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Cell Biology International</title><title level="j" type="alt">CELL BIOLOGY INTERNATIONAL</title><idno type="ISSN">1065-6995</idno><idno type="eISSN">1095-8355</idno><imprint><biblScope unit="vol">38</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="343">343</biblScope><biblScope unit="page" to="354">354</biblScope><biblScope unit="page-count">12</biblScope><date type="published" when="2014-03">2014-03</date></imprint><idno type="ISSN">1065-6995</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1065-6995</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cytotoxic activity of 5,7‐dimethoxy‐2‐phenyl‐N‐propylquinolin‐4‐amine (DMPPQA) was investigated in human colon cancer cells HCT‐116 and umbilical vein endothelial cell line HUVEC. The IC50 of DMPPQA on HCT‐116 and HUVEC cells were respectively 1.26 and 7.43 µM after 72 h treatment. DMPPQA inhibited the growth of HCT‐116 and HUVEC cells in concentration‐ and time‐dependent manners. Typical morphological changes of apoptotic body formation were seen after DMPPQA with Hoechst 33258 staining. FCM analysis showed that DMPPQA induced apoptosis, mitochondrial membrane potential loss (ΔΨm) and increase in the production of intracellular reactive oxygen species (ROS) of HCT‐116 cells. After treating with DMPPQA, apoptosis‐related protein expression of Bax, cytochrome c, caspase‐9, caspase‐3, PARP‐1 and P53 increased and Bcl‐2 protein expression decreased. DMPPQA treatment of HUVECs reduced cell migration and microcapillary tube formation in a Matrigel matrix. It also decreased VEGF protein expression. Thus DMPPQA acts as an angiogenesis inhibitor and induces cell apoptosis by a caspase‐dependent mitochondrial pathway.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Jie Ren</name><affiliations><json:string>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</json:string><json:string>E-mail: renjie2006@163.com</json:string></affiliations></json:item><json:item><name>Hefei Jiang</name><affiliations><json:string>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</json:string></affiliations></json:item><json:item><name>Juan Zhao</name><affiliations><json:string>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</json:string></affiliations></json:item><json:item><name>Wenqun Xin</name><affiliations><json:string>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</json:string></affiliations></json:item><json:item><name>Yuanyuan Xu</name><affiliations><json:string>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</json:string></affiliations></json:item><json:item><name>Xin Chen</name><affiliations><json:string>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</json:string></affiliations></json:item><json:item><name>Kun Hu</name><affiliations><json:string>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</json:string><json:string>E-mail: renjie2006@163.com</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>angiogenesis inhibitor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>apoptosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>DMPPQA</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>mitochondria</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ROS</value></json:item></subject><articleId><json:string>CBIN10209</json:string></articleId><arkIstex>ark:/67375/WNG-TSV254Z3-H</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Cytotoxic activity of 5,7‐dimethoxy‐2‐phenyl‐N‐propylquinolin‐4‐amine (DMPPQA) was investigated in human colon cancer cells HCT‐116 and umbilical vein endothelial cell line HUVEC. The IC50 of DMPPQA on HCT‐116 and HUVEC cells were respectively 1.26 and 7.43 µM after 72 h treatment. DMPPQA inhibited the growth of HCT‐116 and HUVEC cells in concentration‐ and time‐dependent manners. Typical morphological changes of apoptotic body formation were seen after DMPPQA with Hoechst 33258 staining. FCM analysis showed that DMPPQA induced apoptosis, mitochondrial membrane potential loss (ΔΨm) and increase in the production of intracellular reactive oxygen species (ROS) of HCT‐116 cells. After treating with DMPPQA, apoptosis‐related protein expression of Bax, cytochrome c, caspase‐9, caspase‐3, PARP‐1 and P53 increased and Bcl‐2 protein expression decreased. DMPPQA treatment of HUVECs reduced cell migration and microcapillary tube formation in a Matrigel matrix. It also decreased VEGF protein expression. Thus DMPPQA acts as an angiogenesis inhibitor and induces cell apoptosis by a caspase‐dependent mitochondrial pathway.</abstract><qualityIndicators><score>8.54</score><pdfWordCount>4728</pdfWordCount><pdfCharCount>29754</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>12</pdfPageCount><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><pdfWordsPerPage>394</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>151</abstractWordCount><abstractCharCount>1126</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs</title><genre><json:string>article</json:string></genre><host><title>Cell Biology International</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1095-8355</json:string></doi><issn><json:string>1065-6995</json:string></issn><eissn><json:string>1095-8355</json:string></eissn><publisherId><json:string>CBIN</json:string></publisherId><volume>38</volume><issue>3</issue><pages><first>343</first><last>354</last><total>12</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Research Article</value></json:item><json:item><value>Research Articles</value></json:item></subject></host><ark><json:string>ark:/67375/WNG-TSV254Z3-H</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - cell biology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - biochemistry & molecular biology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Cell Biology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - General Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2014</publicationDate><copyrightDate>2014</copyrightDate><doi><json:string>10.1002/cbin.10209</json:string></doi><id>8E8899FCB0D7AFCF310D3D1AC8CD4C12302F5117</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TSV254Z3-H/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TSV254Z3-H/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-TSV254Z3-H/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs</title><title level="a" type="short">DMPPQA induces apoptosis in human colon cancer</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher><availability><licence>© 2013 International Federation for Cell Biology</licence></availability><date type="published" when="2014-03"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs</title><title level="a" type="short">DMPPQA induces apoptosis in human colon cancer</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Jie</forename><surname>Ren</surname></persName><affiliation><orgName type="division">School of Pharmaceutical Engineering & Life Science</orgName><orgName type="institution">Changzhou University</orgName><address><settlement>Changzhou, Jiangsu</settlement><postCode>213164</postCode><region>P.R. China</region></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Hefei</forename><surname>Jiang</surname></persName><affiliation><orgName type="division">School of Pharmaceutical Engineering & Life Science</orgName><orgName type="institution">Changzhou University</orgName><address><settlement>Changzhou, Jiangsu</settlement><postCode>213164</postCode><region>P.R. China</region></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Juan</forename><surname>Zhao</surname></persName><affiliation><orgName type="division">School of Pharmaceutical Engineering & Life Science</orgName><orgName type="institution">Changzhou University</orgName><address><settlement>Changzhou, Jiangsu</settlement><postCode>213164</postCode><region>P.R. China</region></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Wenqun</forename><surname>Xin</surname></persName><affiliation><orgName type="division">School of Pharmaceutical Engineering & Life Science</orgName><orgName type="institution">Changzhou University</orgName><address><settlement>Changzhou, Jiangsu</settlement><postCode>213164</postCode><region>P.R. China</region></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Yuanyuan</forename><surname>Xu</surname></persName><affiliation><orgName type="division">School of Pharmaceutical Engineering & Life Science</orgName><orgName type="institution">Changzhou University</orgName><address><settlement>Changzhou, Jiangsu</settlement><postCode>213164</postCode><region>P.R. China</region></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Xin</forename><surname>Chen</surname></persName><affiliation><orgName type="division">School of Pharmaceutical Engineering & Life Science</orgName><orgName type="institution">Changzhou University</orgName><address><settlement>Changzhou, Jiangsu</settlement><postCode>213164</postCode><region>P.R. China</region></address></affiliation></author><author xml:id="author-0006" role="corresp"><persName><forename type="first">Kun</forename><surname>Hu</surname></persName><affiliation><orgName type="division">School of Pharmaceutical Engineering & Life Science</orgName><orgName type="institution">Changzhou University</orgName><address><settlement>Changzhou, Jiangsu</settlement><postCode>213164</postCode><region>P.R. China</region></address></affiliation></author><idno type="istex">8E8899FCB0D7AFCF310D3D1AC8CD4C12302F5117</idno><idno type="ark">ark:/67375/WNG-TSV254Z3-H</idno><idno type="DOI">10.1002/cbin.10209</idno><idno type="unit">CBIN10209</idno><idno type="toTypesetVersion">file:CBIN.CBIN10209.pdf</idno></analytic><monogr><title level="j" type="main">Cell Biology International</title><title level="j" type="alt">CELL BIOLOGY INTERNATIONAL</title><idno type="pISSN">1065-6995</idno><idno type="eISSN">1095-8355</idno><idno type="book-DOI">10.1002/(ISSN)1095-8355</idno><idno type="book-part-DOI">10.1002/cbin.v38.3</idno><idno type="product">CBIN</idno><imprint><biblScope unit="vol">38</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="343">343</biblScope><biblScope unit="page" to="354">354</biblScope><biblScope unit="page-count">12</biblScope><date type="published" when="2014-03"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>Cytotoxic activity of 5,7‐dimethoxy‐2‐phenyl‐N‐propylquinolin‐4‐amine (DMPPQA) was investigated in human colon cancer cells HCT‐116 and umbilical vein endothelial cell line HUVEC. The IC<hi rend="subscript">50</hi> of DMPPQA on HCT‐116 and HUVEC cells were respectively 1.26 and 7.43 µM after 72 h treatment. DMPPQA inhibited the growth of HCT‐116 and HUVEC cells in concentration‐ and time‐dependent manners. Typical morphological changes of apoptotic body formation were seen after DMPPQA with Hoechst 33258 staining. FCM analysis showed that DMPPQA induced apoptosis, mitochondrial membrane potential loss (ΔΨ<hi rend="italic">m</hi>) and increase in the production of intracellular reactive oxygen species (ROS) of HCT‐116 cells. After treating with DMPPQA, apoptosis‐related protein expression of Bax, cytochrome <hi rend="italic">c</hi>, caspase‐9, caspase‐3, PARP‐1 and P53 increased and Bcl‐2 protein expression decreased. DMPPQA treatment of HUVECs reduced cell migration and microcapillary tube formation in a Matrigel matrix. It also decreased VEGF protein expression. Thus DMPPQA acts as an angiogenesis inhibitor and induces cell apoptosis by a caspase‐dependent mitochondrial pathway.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="cbin10209-kwd-0001">angiogenesis inhibitor</term><term xml:id="cbin10209-kwd-0002">apoptosis</term><term xml:id="cbin10209-kwd-0003"><hi rend="fc">DMPPQA</hi></term><term xml:id="cbin10209-kwd-0004">mitochondria</term><term xml:id="cbin10209-kwd-0005"><hi rend="fc">ROS</hi></term></keywords><keywords rend="articleCategory"><term>Research Article</term></keywords><keywords rend="tocHeading1"><term>Research Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TSV254Z3-H/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" xml:lang="en" type="serialArticle" xml:id="cbin10209"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1002/(ISSN)1095-8355</doi><issn type="print">1065-6995</issn><issn type="electronic">1095-8355</issn><idGroup><id type="product" value="CBIN"></id></idGroup><titleGroup><title type="main" sort="CELL BIOLOGY INTERNATIONAL">Cell Biology International</title><title type="short">Cell Biol Int</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi registered="yes">10.1002/cbin.v38.3</doi><copyright ownership="publisher">© 2013 International Federation for Cell Biology</copyright><numberingGroup><numbering type="journalVolume" number="38">38</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2014-03">March 2014</coverDate></publicationMeta><publicationMeta level="unit" position="80" type="article" status="forIssue"><doi>10.1002/cbin.10209</doi><idGroup><id type="unit" value="CBIN10209"></id></idGroup><countGroup><count type="pageTotal" number="12"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="publisher">© 2013 International Federation for Cell Biology</copyright><eventGroup><event type="manuscriptReceived" date="2013-08-28"></event><event type="manuscriptAccepted" date="2013-10-27"></event><event type="xmlCreated" agent="Thomson Digital" date="2013-11-28"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.2.9 mode:FullText" date="2014-02-04"></event><event type="publishedOnlineAccepted" date="2013-11-12"></event><event type="publishedOnlineEarlyUnpaginated" date="2013-12-02"></event><event type="firstOnline" date="2013-12-02"></event><event type="publishedOnlineFinalForm" date="2014-02-04"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.6.4 mode:FullText" date="2015-10-08"></event></eventGroup><numberingGroup><numbering type="pageFirst">343</numbering><numbering type="pageLast">354</numbering></numberingGroup><correspondenceTo><b>Corresponding authors:</b> e‐mail: <email>renjie2006@163.com</email> (J. R.), <email>hukun1979@163.com</email> (K. H.)</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:CBIN.CBIN10209.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="main"><fc>DMPPQA</fc>, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer <fc>HCT</fc>‐116 cells and <fc>HUVEC</fc>s</title><title type="short">DMPPQA induces apoptosis in human colon cancer</title><title type="shortAuthors">J. Ren <i>et al.</i></title></titleGroup><creators><creator xml:id="cbin10209-cr-0001" creatorRole="author" affiliationRef="#cbin10209-aff-0001" corresponding="yes"><personName><givenNames>Jie</givenNames> <familyName>Ren</familyName></personName></creator><creator xml:id="cbin10209-cr-0002" creatorRole="author" affiliationRef="#cbin10209-aff-0001"><personName><givenNames>Hefei</givenNames> <familyName>Jiang</familyName></personName></creator><creator xml:id="cbin10209-cr-0003" creatorRole="author" affiliationRef="#cbin10209-aff-0001"><personName><givenNames>Juan</givenNames> <familyName>Zhao</familyName></personName></creator><creator xml:id="cbin10209-cr-0004" creatorRole="author" affiliationRef="#cbin10209-aff-0001"><personName><givenNames>Wenqun</givenNames> <familyName>Xin</familyName></personName></creator><creator xml:id="cbin10209-cr-0005" creatorRole="author" affiliationRef="#cbin10209-aff-0001"><personName><givenNames>Yuanyuan</givenNames> <familyName>Xu</familyName></personName></creator><creator xml:id="cbin10209-cr-0006" creatorRole="author" affiliationRef="#cbin10209-aff-0001"><personName><givenNames>Xin</givenNames> <familyName>Chen</familyName></personName></creator><creator xml:id="cbin10209-cr-0007" creatorRole="author" affiliationRef="#cbin10209-aff-0001" corresponding="yes"><personName><givenNames>Kun</givenNames> <familyName>Hu</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="cbin10209-aff-0001" countryCode="CN"><orgDiv>School of Pharmaceutical Engineering & Life Science</orgDiv><orgName>Changzhou University</orgName><address><city>Changzhou, Jiangsu</city><postCode>213164</postCode><countryPart>P.R. China</countryPart></address></affiliation></affiliationGroup><keywordGroup type="author" xml:lang="en"><keyword xml:id="cbin10209-kwd-0001">angiogenesis inhibitor</keyword><keyword xml:id="cbin10209-kwd-0002">apoptosis</keyword><keyword xml:id="cbin10209-kwd-0003"><fc>DMPPQA</fc></keyword><keyword xml:id="cbin10209-kwd-0004">mitochondria</keyword><keyword xml:id="cbin10209-kwd-0005"><fc>ROS</fc></keyword></keywordGroup><fundingInfo><fundingAgency>National Natural Science Foundation of China</fundingAgency><fundingNumber>21202012</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="cbin10209-sec-0001"><p>Cytotoxic activity of 5,7‐dimethoxy‐2‐phenyl‐N‐propylquinolin‐4‐amine (DMPPQA) was investigated in human colon cancer cells HCT‐116 and umbilical vein endothelial cell line HUVEC. The IC<sub>50</sub> of DMPPQA on HCT‐116 and HUVEC cells were respectively 1.26 and 7.43 µM after 72 h treatment. DMPPQA inhibited the growth of HCT‐116 and HUVEC cells in concentration‐ and time‐dependent manners. Typical morphological changes of apoptotic body formation were seen after DMPPQA with Hoechst 33258 staining. FCM analysis showed that DMPPQA induced apoptosis, mitochondrial membrane potential loss (ΔΨ<i>m</i>) and increase in the production of intracellular reactive oxygen species (ROS) of HCT‐116 cells. After treating with DMPPQA, apoptosis‐related protein expression of Bax, cytochrome <i>c</i>, caspase‐9, caspase‐3, PARP‐1 and P53 increased and Bcl‐2 protein expression decreased. DMPPQA treatment of HUVECs reduced cell migration and microcapillary tube formation in a Matrigel matrix. It also decreased VEGF protein expression. Thus DMPPQA acts as an angiogenesis inhibitor and induces cell apoptosis by a caspase‐dependent mitochondrial pathway.</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>DMPPQA induces apoptosis in human colon cancer</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs</title></titleInfo><name type="personal"><namePart type="given">Jie</namePart><namePart type="family">Ren</namePart><affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</affiliation><affiliation>E-mail: renjie2006@163.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hefei</namePart><namePart type="family">Jiang</namePart><affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Juan</namePart><namePart type="family">Zhao</namePart><affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wenqun</namePart><namePart type="family">Xin</namePart><affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yuanyuan</namePart><namePart type="family">Xu</namePart><affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Xin</namePart><namePart type="family">Chen</namePart><affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kun</namePart><namePart type="family">Hu</namePart><affiliation>School of Pharmaceutical Engineering & Life Science, Changzhou University, P.R. China, 213164, Changzhou, Jiangsu</affiliation><affiliation>E-mail: renjie2006@163.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2014-03</dateIssued><dateCreated encoding="w3cdtf">2013-11-28</dateCreated><dateCaptured encoding="w3cdtf">2013-08-28</dateCaptured><dateValid encoding="w3cdtf">2013-10-27</dateValid><copyrightDate encoding="w3cdtf">2014</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Cytotoxic activity of 5,7‐dimethoxy‐2‐phenyl‐N‐propylquinolin‐4‐amine (DMPPQA) was investigated in human colon cancer cells HCT‐116 and umbilical vein endothelial cell line HUVEC. The IC50 of DMPPQA on HCT‐116 and HUVEC cells were respectively 1.26 and 7.43 µM after 72 h treatment. DMPPQA inhibited the growth of HCT‐116 and HUVEC cells in concentration‐ and time‐dependent manners. Typical morphological changes of apoptotic body formation were seen after DMPPQA with Hoechst 33258 staining. FCM analysis showed that DMPPQA induced apoptosis, mitochondrial membrane potential loss (ΔΨm) and increase in the production of intracellular reactive oxygen species (ROS) of HCT‐116 cells. After treating with DMPPQA, apoptosis‐related protein expression of Bax, cytochrome c, caspase‐9, caspase‐3, PARP‐1 and P53 increased and Bcl‐2 protein expression decreased. DMPPQA treatment of HUVECs reduced cell migration and microcapillary tube formation in a Matrigel matrix. It also decreased VEGF protein expression. Thus DMPPQA acts as an angiogenesis inhibitor and induces cell apoptosis by a caspase‐dependent mitochondrial pathway.</abstract><note type="funding">National Natural Science Foundation of China - No. 21202012; </note><subject lang="en"><genre>keywords</genre><topic>angiogenesis inhibitor</topic><topic>apoptosis</topic><topic>DMPPQA</topic><topic>mitochondria</topic><topic>ROS</topic></subject><relatedItem type="host"><titleInfo><title>Cell Biology International</title></titleInfo><titleInfo type="abbreviated"><title>Cell Biol Int</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Research Article</topic><topic>Research Articles</topic></subject><identifier type="ISSN">1065-6995</identifier><identifier type="eISSN">1095-8355</identifier><identifier type="DOI">10.1002/(ISSN)1095-8355</identifier><identifier type="PublisherID">CBIN</identifier><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>343</start><end>354</end><total>12</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0001"><titleInfo><title>ROS, stress‐activated kinases and stress signaling in cancer</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Benhar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Engelberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Levitzki</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Benhar M, Engelberg D, Levitzki A (2002) ROS, stress‐activated kinases and stress signaling in cancer. EMBO J 3: 420–5.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>420</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>EMBO J</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>420</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0002"><titleInfo><title>Anticancer therapeutics: “Addictive” targets, multi‐targeted drugs, new drug combinations</title></titleInfo><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">Broxterman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NH</namePart><namePart type="family">Georgopapadakou</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Broxterman HJ, Georgopapadakou NH (2005) Anticancer therapeutics: “Addictive” targets, multi‐targeted drugs, new drug combinations. Drug Resist Updat 8: 183–97.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>183</start><end>97</end></extent></part><relatedItem type="host"><titleInfo><title>Drug Resist Updat</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>183</start><end>97</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0003"><titleInfo><title>Synthesis and anticonvulsant evaluation of 4‐(4‐alkoxylphenyl)‐3‐ethyl‐4H‐1,2,4‐triazoles as open‐chain analogues of 7‐alkoxyl‐4,5‐dihydro[1,2,4]triazolo[4,3‐a] quinolines</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XY</namePart><namePart type="family">Sun</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KY</namePart><namePart type="family">Chai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Less</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MS</namePart><namePart type="family">Song</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZS</namePart><namePart type="family">Quan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chen J, Sun XY, Chai KY, Less JS, Song MS, Quan ZS (2007) Synthesis and anticonvulsant evaluation of 4‐(4‐alkoxylphenyl)‐3‐ethyl‐4H‐1,2,4‐triazoles as open‐chain analogues of 7‐alkoxyl‐4,5‐dihydro[1,2,4]triazolo[4,3‐a] quinolines. Bioorg Med Chem 21: 6775–81.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>6775</start><end>81</end></extent></part><relatedItem type="host"><titleInfo><title>Bioorg Med Chem</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>6775</start><end>81</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0004"><titleInfo><title>Kinetin riboside preferentially induces apoptosis by modulating Bcl‐2 family proteins and caspase‐3 in cancer cells</title></titleInfo><name type="personal"><namePart type="given">BH</namePart><namePart type="family">Choi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">QC</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DC</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SN</namePart><namePart type="family">Tan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JW</namePart><namePart type="family">Yong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KT</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HS</namePart><namePart type="family">Yoon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Choi BH, Kim W, Wang QC, Kim DC, Tan SN, Yong JW, Kim KT, Yoon HS (2008) Kinetin riboside preferentially induces apoptosis by modulating Bcl‐2 family proteins and caspase‐3 in cancer cells. Cancer Lett 261: 37–45.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>261</number></detail><extent unit="pages"><start>37</start><end>45</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Lett</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>261</number></detail><extent unit="pages"><start>37</start><end>45</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0005"><titleInfo><title>Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Fellgiebel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Hiemke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Bartenstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Müller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Schreckenberger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fellgiebel A, Hiemke C, Bartenstein P, Müller MJ, Schreckenberger M (2007) Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry 2: 123–6.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>123</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>World J Biol Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>123</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0006"><titleInfo><title>Antitumor effect of substituted quinolines in breast cancer cells</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Gakhar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ohira</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AB</namePart><namePart type="family">Shi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DH</namePart><namePart type="family">Hua</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TA</namePart><namePart type="family">Nguyen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gakhar G, Ohira T, Shi AB, Hua DH, Nguyen TA (2008) Antitumor effect of substituted quinolines in breast cancer cells. Drug Dev Res 69: 526–34.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>526</start><end>34</end></extent></part><relatedItem type="host"><titleInfo><title>Drug Dev Res</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>526</start><end>34</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0007"><titleInfo><title>Enhanced oxaliplatin‐induced apoptosis following antisense Bcl‐xl down‐regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect</title></titleInfo><name type="personal"><namePart type="given">RL</namePart><namePart type="family">Hayward</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Macpherson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Cummings</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BP</namePart><namePart type="family">Monia</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JF</namePart><namePart type="family">Smyth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DI</namePart><namePart type="family">Jodrell</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI (2004) Enhanced oxaliplatin‐induced apoptosis following antisense Bcl‐xl down‐regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3: 169–78.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>169</start><end>78</end></extent></part><relatedItem type="host"><titleInfo><title>Mol Cancer Ther</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>169</start><end>78</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0008"><titleInfo><title>Synthesis and anticonvulsant activity of 1‐(8‐(benzyloxy)quinolin‐2‐yl)‐6‐Substituted‐4,6‐diazaspiro[2,4]heptane‐5,7‐diones</title></titleInfo><name type="personal"><namePart type="given">X</namePart><namePart type="family">He</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Zhong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Z</namePart><namePart type="family">Wu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Xiao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Guo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Qiu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Hu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">He X, Zhong M, Zhang T, Yang J, Wu Z, Xiao Y, Guo H, Qiu G, Hu X (2012) Synthesis and anticonvulsant activity of 1‐(8‐(benzyloxy)quinolin‐2‐yl)‐6‐Substituted‐4,6‐diazaspiro[2,4]heptane‐5,7‐diones. Eur J Med Chem 48: 338–46.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>338</start><end>46</end></extent></part><relatedItem type="host"><titleInfo><title>Eur J Med Chem</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>338</start><end>46</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0009"><titleInfo><title>Design and structure‐activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors</title></titleInfo><name type="personal"><namePart type="given">LF</namePart><namePart type="family">Hennequin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AP</namePart><namePart type="family">Thomas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Johnstone</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ES</namePart><namePart type="family">Stokes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Plé</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JJ</namePart><namePart type="family">Lohmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Ogilvie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Dukes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SR</namePart><namePart type="family">Wedge</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JO</namePart><namePart type="family">Curwen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kendrew</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Lambert‐van der Brempt</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert‐van der Brempt C (1999) Design and structure‐activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 42: 5369–89.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>5369</start><end>89</end></extent></part><relatedItem type="host"><titleInfo><title>J Med Chem</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>5369</start><end>89</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0010"><titleInfo><title>Hyperplasia of lymphatic vessels in VEGF‐C transgenic mice</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Jeltsch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kaipainen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Joukov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Meng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Lakso</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Rauvala</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Swartz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Fukumura</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RK</namePart><namePart type="family">Jain</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Alitalo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K (1997) Hyperplasia of lymphatic vessels in VEGF‐C transgenic mice. Science 276: 1423–5.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>276</number></detail><extent unit="pages"><start>1423</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>276</number></detail><extent unit="pages"><start>1423</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0011"><titleInfo><title>Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8‐quinolinamines</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Kaur</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SR</namePart><namePart type="family">Patel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Patil</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Jain</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SI</namePart><namePart type="family">Khan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MR</namePart><namePart type="family">Jacob</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ganesan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BL</namePart><namePart type="family">Tekwani</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Jain</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kaur K, Patel SR, Patil P, Jain M, Khan SI, Jacob MR, Ganesan S, Tekwani BL, Jain R (2007) Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8‐quinolinamines. Bioorg Med Chem 2: 915–30.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>915</start><end>30</end></extent></part><relatedItem type="host"><titleInfo><title>Bioorg Med Chem</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>915</start><end>30</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0012"><titleInfo><title>Synthesis of isoquinuclidine analogs of chloroquine: antimalarial and antileishmanial activity</title></titleInfo><name type="personal"><namePart type="given">MO</namePart><namePart type="family">Khan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MS</namePart><namePart type="family">Levi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BL</namePart><namePart type="family">Tekwani</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NH</namePart><namePart type="family">Wilson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RF</namePart><namePart type="family">Borne</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Khan MO, Levi MS, Tekwani BL, Wilson NH, Borne RF (2007) Synthesis of isoquinuclidine analogs of chloroquine: antimalarial and antileishmanial activity. Bioorg Med Chem 11: 3919–25.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>3919</start><end>25</end></extent></part><relatedItem type="host"><titleInfo><title>Bioorg Med Chem</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>3919</start><end>25</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0013"><titleInfo><title>Diarylquinolines target subunit c of mycobacterial ATP synthase</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Koul</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Dendouga</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Vergauwen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Molenberghs</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Vranckx</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Willebrords</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Z</namePart><namePart type="family">Ristic</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Lill</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Dorange</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Guillemont</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Bald</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Andries</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D, Andries K (2007) Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 6: 323–4.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>323</start><end>4</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Chem Biol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>323</start><end>4</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0014"><titleInfo><title>Cancer. p53, guardian of the genome</title></titleInfo><name type="personal"><namePart type="given">DP</namePart><namePart type="family">Lane</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358: 15–6.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>358</number></detail><extent unit="pages"><start>15</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>358</number></detail><extent unit="pages"><start>15</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0015"><titleInfo><title>Angiogenesis: regulators and clinical applications</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Liekens</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">DeClercq</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Neyts</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liekens S, DeClercq E, Neyts J (2001) Angiogenesis: regulators and clinical applications, Biochem Pharmacol 61: 253–70.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>253</start><end>70</end></extent></part><relatedItem type="host"><titleInfo><title>Biochem Pharmacol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>253</start><end>70</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0016"><titleInfo><title>Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the MTOR inhibitor RAD001</title></titleInfo><name type="personal"><namePart type="given">CR</namePart><namePart type="family">Loehberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PL</namePart><namePart type="family">Strissel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Dittrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Strick</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Dittmer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Dittmer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Fabry</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WA</namePart><namePart type="family">Kalender</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Koch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DL</namePart><namePart type="family">Wachter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Groh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Polier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Brandt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Lotz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Hoffmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Koppitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Oeser</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Mueller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Fasching</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MP</namePart><namePart type="family">Lux</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MW</namePart><namePart type="family">Beckmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MG</namePart><namePart type="family">Schrauder</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, Fabry B, Kalender WA, Koch T, Wachter DL, Groh N, Polier A, Brandt I, Lotz L, Hoffmann I, Koppitz F, Oeser S, Mueller A, Fasching PA, Lux MP, Beckmann MW, Schrauder MG (2012) Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the MTOR inhibitor RAD001. Biochem Pharmacol 4: 480–8.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>480</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Biochem Pharmacol</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>480</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0017"><titleInfo><title>The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update</title></titleInfo><name type="personal"><namePart type="given">JD</namePart><namePart type="family">Ly</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DR</namePart><namePart type="family">Grubb</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Lawen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ly JD, Grubb DR, Lawen A (2003) The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis 8: 115–28.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>115</start><end>28</end></extent></part><relatedItem type="host"><titleInfo><title>Apoptosis</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>115</start><end>28</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0018"><titleInfo><title>A new series of PDGF receptor tyrosine kinase inhibitors:3‐substituted quinoline derivatives</title></titleInfo><name type="personal"><namePart type="given">MP</namePart><namePart type="family">Maguire</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KR</namePart><namePart type="family">Sheets</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">McVety</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AP</namePart><namePart type="family">Spada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Zilberstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Maguire MP, Sheets KR, McVety K, Spada AP, Zilberstein A (1994) A new series of PDGF receptor tyrosine kinase inhibitors:3‐substituted quinoline derivatives. J Med Chem 14: 2129–37.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>2129</start><end>37</end></extent></part><relatedItem type="host"><titleInfo><title>J Med Chem</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>2129</start><end>37</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0019"><titleInfo><title>Phase I/II trial of a P‐glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with nonHodgkin's lymphoma</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Morschhauser</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PL</namePart><namePart type="family">Zinzani</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Burgess</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Sloots</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Bouafia</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Dumontet</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C (2007) Phase I/II trial of a P‐glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with nonHodgkin's lymphoma. Leuk Lymphoma 4: 708–15.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>708</start><end>15</end></extent></part><relatedItem type="host"><titleInfo><title>Leuk Lymphoma</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>708</start><end>15</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0020"><titleInfo><title>Novel pyrrolo‐quinoline derivatives as potent inhibitors for PI3‐kinase related kinases</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Peng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DI</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JN</namePart><namePart type="family">Sarkaria</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YS</namePart><namePart type="family">Cho</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RT</namePart><namePart type="family">Abraham</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LH</namePart><namePart type="family">Zalkow</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Peng H, Kim DI, Sarkaria JN, Cho YS, Abraham RT, Zalkow LH (2002) Novel pyrrolo‐quinoline derivatives as potent inhibitors for PI3‐kinase related kinases. Bioorg Med Chem 10: 167–74.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>167</start><end>74</end></extent></part><relatedItem type="host"><titleInfo><title>Bioorg Med Chem</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>167</start><end>74</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0021"><titleInfo><title>Targeting of VEGF‐dependent transendothelial migration of cancer cells by bevacizumab</title></titleInfo><name type="personal"><namePart type="given">GW</namePart><namePart type="family">Prager</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Lackner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MT</namePart><namePart type="family">Krauth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Unseld</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Poettler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Laffer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Cerny‐Reiterer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Lamm</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GV</namePart><namePart type="family">Kornek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BR</namePart><namePart type="family">Binder</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CC</namePart><namePart type="family">Zielinski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Valent</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Prager GW, Lackner EM, Krauth MT, Unseld M, Poettler M, Laffer S, Cerny‐Reiterer S, Lamm W, Kornek GV, Binder BR, Zielinski CC, Valent P (2010) Targeting of VEGF‐dependent transendothelial migration of cancer cells by bevacizumab. Mol Oncol 2: 150–60.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>150</start><end>60</end></extent></part><relatedItem type="host"><titleInfo><title>Mol Oncol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>150</start><end>60</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0022"><titleInfo><title>Lunacridine from Lunasia amara is a DNA intercalating topoisomerase II inhibitor</title></titleInfo><name type="personal"><namePart type="given">TA</namePart><namePart type="family">Prescott</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IH</namePart><namePart type="family">Sadler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Kiapranis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SK</namePart><namePart type="family">Maciver</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Prescott TA, Sadler IH, Kiapranis R, Maciver SK (2007) Lunacridine from Lunasia amara is a DNA intercalating topoisomerase II inhibitor. J Ethnopharmacol 2: 289–94.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>289</start><end>94</end></extent></part><relatedItem type="host"><titleInfo><title>J Ethnopharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>289</start><end>94</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0023"><titleInfo><title>Synthesis and antitumor activity of novel 4‐aminoquinoline derivatives</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Ren</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Zhao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YS</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XH</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Hu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ren J, Zhao J, Zhou YS, Liu XH, Chen X, Hu K (2012) Synthesis and antitumor activity of novel 4‐aminoquinoline derivatives. Med Chem Res DOI: 10.1007/s00044‐012‐0283‐8</note><part><date>2012</date></part><relatedItem type="host"><titleInfo><title>Med Chem Res</title></titleInfo><part><date>2012</date></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0024"><titleInfo><title>The pathogenesis of atherosclerosis: a perspective for the 1990s</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Ross</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801–9.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>362</number></detail><extent unit="pages"><start>801</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>362</number></detail><extent unit="pages"><start>801</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0025"><titleInfo><title>The pathogenesis of atherosclerosis (second of two parts)</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Ross</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Glomset</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ross R, Glomset JA (1976) The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 295: 420–5.</note><part><date>1976</date><detail type="volume"><caption>vol.</caption><number>295</number></detail><extent unit="pages"><start>420</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>1976</date><detail type="volume"><caption>vol.</caption><number>295</number></detail><extent unit="pages"><start>420</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0026"><titleInfo><title>Sulindac sulfide‐induced apoptosis is enhanced by a small‐molecule Bcl‐2 inhibitor and by TRAIL in human colon cancer cells over‐expressing Bcl‐2</title></titleInfo><name type="personal"><namePart type="given">FA</namePart><namePart type="family">Sinicrope</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RC</namePart><namePart type="family">Penington</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sinicrope FA, Penington RC (2005) Sulindac sulfide‐induced apoptosis is enhanced by a small‐molecule Bcl‐2 inhibitor and by TRAIL in human colon cancer cells over‐expressing Bcl‐2. Mol Cancer Ther 4: 1475–83.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>1475</start><end>83</end></extent></part><relatedItem type="host"><titleInfo><title>Mol Cancer Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>1475</start><end>83</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0027"><titleInfo><title>Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies</title></titleInfo><name type="personal"><namePart type="given">VR</namePart><namePart type="family">Solomon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Solomon VR, Lee H (2009) Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 625: 220–33.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>625</number></detail><extent unit="pages"><start>220</start><end>33</end></extent></part><relatedItem type="host"><titleInfo><title>Eur J Pharmacol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>625</number></detail><extent unit="pages"><start>220</start><end>33</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0028"><titleInfo><title>Antimalarial activity of novel pyrrolizidinyl derivatives of 4‐aminoquinoline</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Sparatore</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Basilico</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Manolo Casaqrande</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Parapini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Taramelli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Brun</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Wittlin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Sparatore</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sparatore A, Basilico N, Manolo Casaqrande M, Parapini S, Taramelli D, Brun R, Wittlin S, Sparatore F (2008) Antimalarial activity of novel pyrrolizidinyl derivatives of 4‐aminoquinoline. Bioorg Med Chem Lett 13: 3737–40.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>3737</start><end>40</end></extent></part><relatedItem type="host"><titleInfo><title>Bioorg Med Chem Lett</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>3737</start><end>40</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0029"><titleInfo><title>Caspase: enemies within</title></titleInfo><name type="personal"><namePart type="given">NA</namePart><namePart type="family">Thornberry</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Lazebnik</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thornberry NA, Lazebnik Y (1998) Caspase: enemies within. Science 281: 1308–16.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>281</number></detail><extent unit="pages"><start>1308</start><end>16</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>281</number></detail><extent unit="pages"><start>1308</start><end>16</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0030"><titleInfo><title>Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis</title></titleInfo><name type="personal"><namePart type="given">MC</namePart><namePart type="family">Wasko</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HB</namePart><namePart type="family">Hubert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VB</namePart><namePart type="family">Lingala</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JR</namePart><namePart type="family">Elliott</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Luggen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JF</namePart><namePart type="family">Fries</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MM</namePart><namePart type="family">Ward</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM (2007) Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2: 187–93.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>187</start><end>93</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>187</start><end>93</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0031"><titleInfo><title>Cellular responses to cancer chemopreventive agent d,l‐sulforaphane in human prostate cancer cells are initiated by mitochondrial reactive oxygen species</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Xiao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AA</namePart><namePart type="family">Powolny</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Antosiewicz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ER</namePart><namePart type="family">Hahm</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Bommareddy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Zeng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Desai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Amin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Herman‐Antosiewicz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SV</namePart><namePart type="family">Singh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Xiao D, Powolny AA, Antosiewicz J, Hahm ER, Bommareddy A, Zeng Y, Desai D, Amin S, Herman‐Antosiewicz A, Singh SV (2009) Cellular responses to cancer chemopreventive agent d,l‐sulforaphane in human prostate cancer cells are initiated by mitochondrial reactive oxygen species. Pharm Res 26: 1729–38.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>1729</start><end>38</end></extent></part><relatedItem type="host"><titleInfo><title>Pharm Res</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>1729</start><end>38</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0032"><titleInfo><title>A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl‐2 family members induces apoptosis and enhances chemosensitivity in androgen‐independent human prostate cancer PC3 cells</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Yamanaka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Rocchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Miyake</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Fazli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Vessella</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Zangemeister‐Wittke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Gleave</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister‐Wittke U, Gleave ME (2005) A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl‐2 family members induces apoptosis and enhances chemosensitivity in androgen‐independent human prostate cancer PC3 cells. Mol Cancer Ther 4: 1689–98.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>1689</start><end>98</end></extent></part><relatedItem type="host"><titleInfo><title>Mol Cancer Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>1689</start><end>98</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cbin10209-cit-0033"><titleInfo><title>The effect of hyaluronic acid on IL‐1beta‐induced chondrocyte apoptosis in a ratmodel of osteoarthritis</title></titleInfo><name type="personal"><namePart type="given">PH</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SQ</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Peng</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhou PH, Liu SQ, Peng H (2008) The effect of hyaluronic acid on IL‐1beta‐induced chondrocyte apoptosis in a ratmodel of osteoarthritis. J Orthop Res 6: 1643–8.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>1643</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>J Orthop Res</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>1643</start><end>8</end></extent></part></relatedItem></relatedItem><identifier type="istex">8E8899FCB0D7AFCF310D3D1AC8CD4C12302F5117</identifier><identifier type="ark">ark:/67375/WNG-TSV254Z3-H</identifier><identifier type="DOI">10.1002/cbin.10209</identifier><identifier type="ArticleID">CBIN10209</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2013 International Federation for Cell Biology© 2013 International Federation for Cell Biology</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-14</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TSV254Z3-H/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000394 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000394 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8E8899FCB0D7AFCF310D3D1AC8CD4C12302F5117
|texte= DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs
}}
| This area was generated with Dilib version V0.6.33. |  |